OnKure Therapeutics (OKUR) Share-based Compensation (2020 - 2026)

OnKure Therapeutics (OKUR) has reported Share-based Compensation for 7 consecutive years, with $4.1 million the latest figure, recorded in Q2 2026.

• For the quarter ending Q2 2026, Share-based Compensation rose 33.73% year-over-year to $4.1 million; the trailing twelve-month figure through Jun 2026 stood at $4.1 million (up 33.73% YoY), and the FY2025 full-year result was $19.9 million, down 24.91% from the prior year.
• Share-based Compensation improved to $4.1 million in Q2 2026 per OKUR's latest filing, from $2.8 million in the prior quarter.
• Across five years, Share-based Compensation topped out at $6.1 million in Q3 2023 and bottomed at -$3.6 million in Q4 2023.
• Historically, Share-based Compensation has averaged $3.4 million across 5 years, with a median of $3.6 million in 2025.
• The sharpest annual moves came in 2023 and 2025: Share-based Compensation slumped 393.67% in 2023, then soared 533.87% in 2025.
• Over 5 years, Share-based Compensation stood at $1.2 million in 2022, then plunged by 393.67% to -$3.6 million in 2023, then jumped by 170.87% to $2.5 million in 2024, then gained by 19.19% to $3.0 million in 2025, then soared by 35.28% to $4.1 million in 2026.
• According to Business Quant data, Share-based Compensation over the past three periods registered $4.1 million, $2.8 million, and $3.0 million for Q2 2026, Q1 2026, and Q4 2025 respectively.